{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-002267","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.394365+00:00","generated_at":"2026-05-15T03:15:46.656229+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silexion submits Phase 2/3 trial application to Germany's BfArM for SIL204 in KRAS-driven pancreatic cancer","bullets":["Silexion submitted CTA to Germany’s BfArM for Phase 2/3 trial of SIL204 in KRAS-driven locally advanced pancreatic cancer.","Germany will serve as EU Reference Member State; trial initiation remains on track for Q2 2026.","Submission supported by completed two-species toxicology studies confirming no systemic organ toxicity.","Planned trial will evaluate SIL204 in combination with standard chemotherapy using dual-route administration.","Pancreatic cancer has <13% five-year survival; KRAS mutations present in about 90% of cases."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002267","json":"https://secwatch.observer/filing/0001178913-26-002267.json","markdown":"https://secwatch.observer/filing/0001178913-26-002267.md","text":"https://secwatch.observer/filing/0001178913-26-002267.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002267/0001178913-26-002267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002267/zk2635144.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:15:46.656229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}